艾立布林真实世界中治疗晚期乳腺癌的疗效

Efficacy of eribulin in the treatment of advanced breast cancer in the real world

目的 观察艾立布林真实世界中治疗晚期乳腺癌的疗效及其与临床病理特征的相关性。方法 回顾性分析2021年4月—2022年6月于安徽医科大学第一附属医院、安徽医科大学第二附属医院、中国科学技术大学附属第一医院接受艾立布林治疗的64例晚期乳腺癌患者临床资料。采用Kaplan-Meier法计算患者无进展生存期(PFS),采用Log-rank法分析各临床因素对PFS的影响。将单因素分析差异有统计学意义的变量纳入多因素Cox回归进行分析,得到影响艾立布林疗效的独立危险因素。结果 64例患者中位PFS为4.0个月,客观缓解率为21.9%(14/64),疾病控制率为70.3%(45/64)。艾立布林联合其他药物治疗晚期乳腺癌患者的中位PFS为5.0个月(95%CI:3.11~5.88个月),长于艾立布林单药治疗患者的3.0个月(95%CI:2.38~3.61个月)(χ^(2)=8.302,P=0.004)。一、二线接受艾立布林治疗的患者中位PFS为7.0个月(95%CI:3.77~10.22个月),三线及以上接受艾立布林患者的中位PFS为3.0个月(95%CI:2.74~3.25个月)(χ^(2)=11.905,P=0.001)。艾立布林的治疗线数为PFS独立预测因素(P=0.010)。结论 艾立布林治疗晚期乳腺癌具有显著疗效,尤其是早线接受艾立布林治疗患者具有更优的生存获益。

Objective To observe the efficacy of eribulin in the treatment of advanced breast cancer in the real world and its correlation with clinicopathological characteristics.Methods The clinical data of 64 patients with advanced breast cancer who were treated with eribulin in the First Affiliated Hospital of Anhui Medical University,the Second Hospital of Anhui Medical University and the First Affiliated Hospital of USTC from April 2021 to June 2022 were retrospectively analyzed.Kaplan-Meier method was used to calculate the progression free survival(PFS)of patients,and Log-rank method was used to analyze the influence of clinical factors on PFS.The variables with statistically significant differences in univariate analysis were included in the multivariate Cox regression analysis,and the independent risk factors affecting the efficacy of eribulin were obtained.Results The median PFS of 64 patients was 4.0 months,the ORR was 21.9%(14/64),and the DCR was 70.3%(45/64).The median PFS of patients with advanced breast cancer treated with eribulin combined with other drugs was 5.0 months(95%CI:3.11-5.88 months),which was longer than that of patients treated with eribulin monotherapy of 3.0 months(95%CI:2.38-3.61 months)(χ^(2)=8.302,P=0.004).The median PFS of patients receiving eribulin from line 1 to line 2 was 7.0 months(95%CI:3.77-10.22 months),and the median PFS of patients receiving eribulin from line≥3 was 3.0 months(95%CI:2.74-3.25 months)(χ^(2)=11.905,P=0.001).The number of treatment lines of eribulin was an independent predictor of PFS(P=0.010).Conclusion Eribulin has significant curative effect in the treatment of advanced breast cancer,especially for patients who receive aribrin early has better survival benefit.